首页|黄帝内针联合铋剂四联疗法治疗慢性萎缩性胃炎伴幽门螺杆菌感染的临床疗效及对肠道微生物菌群和炎症因子的影响

黄帝内针联合铋剂四联疗法治疗慢性萎缩性胃炎伴幽门螺杆菌感染的临床疗效及对肠道微生物菌群和炎症因子的影响

扫码查看
目的 观察黄帝内针联合铋剂四联疗法治疗慢性萎缩性胃炎(CAG)伴幽门螺杆菌(Hp)感染的临床疗效及对肠道微生物菌群和炎症因子的影响.方法 将144 例CAG伴Hp感染患者按照随机数字表法分为2 组,对照组72例予铋剂四联疗法治疗,治疗组72 例在对照组治疗基础上加用黄帝内针治疗,2 组均治疗2 周.比较2 组临床疗效、Hp根除率和治疗期间不良反应情况,比较 2 组治疗前后炎症因子血清白细胞介素 6(IL-6)、IL-1β、肿瘤坏死因子 α(TNF-α)水平及肠道微生物菌群变化.结果 治疗组总有效率88.89%(64/72),对照组总有效率72.22%(52/72),治疗组临床疗效优于对照组(P<0.05).治疗组Hp根除率91.67%(66/72),对照组Hp根除率 81.94%(59/72),治疗组Hp根除率高于对照组(P<0.05).2 组治疗后血清IL-6、IL-1β、TNF-α水平均较本组治疗前降低(P<0.05),且治疗组均低于对照组(P<0.05).治疗后2 组乳酸杆菌、双歧杆菌含量均较本组治疗前升高(P<0.05),肠球菌、肠杆菌、葡萄球菌、产气荚膜梭菌含量均较本组治疗前降低(P<0.05).治疗后治疗组乳酸杆菌、双歧杆菌含量均高于对照组(P<0.05),肠球菌、肠杆菌、葡萄球菌、产气荚膜梭菌含量均低于对照组(P<0.05).治疗组不良反应发生率 8.33%(6/72),对照组不良反应发生率6.94%(5/72),2 组不良反应发生率比较差异无统计学意义(P>0.05).结论 黄帝内针联合铋剂四联疗法治疗CAG伴Hp感染疗效确切,可提高Hp根除率,调节肠道菌群,抑制炎症相关因子水平,且安全可靠.
Clinical efficacy of Huangdi internal acupuncture combined with bismuth quadruple therapy on chronic atrophic gastri-tis with Helicobacter pylori infection and its influence on intestinal microecology and inflammatory factors
Objective This study aimed to assess the therapeutic efficacy of combining Huangdi internal acupuncture with bismuth quadruple therapy in patients with chronic atrophic gastritis(CAG)with Helicobacter pylori(HP)infection,and to explore its influence on intestinal microecology and inflammatory factors.Methods A total of 144 CAG patients with Hp infec-tion were recruited from our hospital and divided into the control group(n=72)and the treatment group(n=72)by a random number table.All patients received bismuth quadruple therapy,and those in the treatment group additionally received Huangdi internal acupuncture.The treatment duration was 2 weeks,aiming to compare the therapeutic efficacy,Hp eradication rate,treatment-emergent adverse event(TEAE),changs in inflammatory factors(including interleukin6[IL-6],IL-1β,tumor necrosis factor α[TNF-α])and intestinal microflora between groups before and after treatment.Results The total effective rates in the treatment group was significantly higher than that of the control group(88.89%[64/72]vs 72.22%[52/72],P<0.05).The Hp eradication rate in the treatment group was significantly higher than that of the control group(91.67%[66/72]vs 81.94%[59/72],P<0.05).After treatment,the serum levels of IL-1β,IL-6 and TNF-α significantly decreased in the both groups(P<0.05).However,the decrease in the treat-ment group was more pronounced relative to the control group(P<0.05).After treatment,the levels of Lactobacillus and Bifidobacterium significantly increased in the both groups,while the levels of Enterococcus,Enterobacter,Staphylococcus,and Clostridium perfringens decreased significantly(P<0.05).Im-portantly,the improvements in the treatment group were more common compared to the control group(P<0.05).There was no significant difference in TEAE between the treatment group and control group(8.33%[6/72]vs 6.94%[5/72],P>0.05).Conclusion The combination of Huangdi internal acupuncture and bismuth quadruple therapy demonstrates a clear therapeutic effect in CAG patients with Hp infection.It can increase Hp eradication rate,regulate intestinal flora,inhibit inflammation-re-lated factors level,and it is safe and reliable.

Atrophic gastritisHelicobacter pyloriHuangdi internal acupunctureIntestinal microecologyInflammato-ry factors

杨丽美、陈建权、宋立杰、马明会、李东辉、谭芝、郎晓猛

展开 >

河北省玉田县中医医院消化科,河北 玉田 064100

河北省中医院脾胃病一科,河北 石家庄 050011

胃炎,萎缩性 幽门螺杆菌 黄帝内针 胃肠道微生物组 炎症因子

河北省中医药管理局2021年度中医药类科研计划课题

2021425

2024

河北中医
河北省医学情报研究所,河北省中医药学会

河北中医

CSTPCD
影响因子:0.951
ISSN:1002-2619
年,卷(期):2024.46(7)
  • 16